MANNHEIM, Germany, June 05, 2024 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving back patients’ natural ability to fight cancer, announced today that it will release financial results for the first quarter of 2024 and a corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.
The conference call will be available via phone and webcast. The live audio webcast of the call will be accessible in the “Webcasts” section of the “Investors” page of the Affimed website at . To access the call by phone, please use this link , and you will be given dial-in details and a pin number.
Note: To avoid delays, participants are encouraged to dial into the conference call 15 minutes before the scheduled start time. A replay of the webcast will be accessible via the same link for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company focused on restoring patients’ innate ability to combat cancer by realizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) facilitate a tumor-specific approach to detect and eradicate various hematological and solid tumors. ICE® molecules are developed on the Company’s exclusive ROCK® platform, which reliably generates tailored molecules that leverage innate immune cells to destroy cancer cells. Numerous ICE® molecules are undergoing clinical evaluation as monotherapies or in combination therapies. With headquarters in Mannheim, Germany, Affimed is led by a team of accomplished biotechnology and pharmaceutical executives who share a bold vision of eradicating cancer’s ability to disrupt patients’ lives. Visit to learn more about the Company’s staff, pipeline, and partners.
Contact for Investor Relations
Alexander Fudukidis
Director and Head of Investor Relations
E-Mail:
Tel.: +1 (917) 436-8102
